BOSTON, MA– Delve Bio announced new data demonstrating that its flagship infectious disease test, Delve Detect, can accurately identify both viruses and their subtypes using a single metagenomic next-generation sequencing (mNGS) test. The findings will be presented on May 8 at the Pan American Society for Clinical Virology (PASCV) Annual Meeting in Clearwater, Florida.
The company’s proprietary bioinformatics platform, Delve Decide, enabled detailed subtyping of several viruses, including HIV, enterovirus, West Nile virus, varicella-zoster virus, and St. Louis encephalitis virus. The results were found to be consistent with traditional, independent subtyping methods.
“Knowing what virus a patient has is only part of the story,” said Brian O’Donovan, Ph.D., head of bioinformatics at Delve Bio. “Identifying the subtype can help clinicians determine if a case is part of an outbreak, poses heightened risks, or requires a change in treatment—all without the need for multiple tests or delays.”
Delve Detect uses unbiased mNGS to scan patient samples for a wide range of pathogens and delivers results within 48 hours. By eliminating the need for sequential testing, the platform aims to speed up diagnosis and inform better clinical decisions—particularly for patients with serious central nervous system (CNS) infections.
“This is a game-changer for infectious disease diagnostics,” said Dr. Steve Miller, chief medical officer at Delve Bio. “With just one test, we can now identify not only the pathogen but also critical subtyping information that can directly impact patient care.”
The data will be featured in a poster presentation titled Rapid, Simultaneous Viral Pathogen Detection, Subtyping and Strain Differentiation Through Unbiased Metagenomic Sequencing With Delve Detect CSF on May 8 at 2:45 p.m. The company’s broader presence at PASCV includes a presentation by UCSF professor and Delve co-founder Dr. Charles Chiu on mNGS for CNS infections.
Delve Detect, built on technology developed at UCSF and exclusively licensed to Delve Bio, also includes support from the company’s Clinical Microbial Sequencing Board—a team of infectious disease specialists who help interpret test results in clinical context.
